CancerCANCERNCT07904247
CANCER SCREENING PROGRAM ON UNCERTAINTY, ANTİCİPATORY ANXIETY, CANCER AWARENESS, AND E-HEALTH LITERACY IN A STROKE PATIENTS
A study testing CANCER SCREENING PROGRAM in people with Cancer and Stroke, run by Ondokuz Mayıs University at 1 site in Turkey (Türkiye).
Trial summary
This research aims to evaluate the impact of a cancer awareness education program (Cancer Awareness Programme Via Digital Health Literacy - DigiCAP), designed to enhance digital literacy and applied to stroke patients, on uncertainty, anticipatory anxiety, and cancer awareness. Read more about this study
- Who is it for?
- Ages 50 years and older
- What is being tested?
- CANCER SCREENING PROGRAM
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2025to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- • Having been diagnosed with a stroke,
- Being 50 years of age or older,
- Being literate,
- Patients with a stroke who are able to communicate will be included in the study. • Having a smartphone or computer,
- Having internet access. • Having been diagnosed with an ischemic stroke,
Who cannot join
- • Having impaired vision, hearing, and speech due to a stroke,
- Having any health problem that hinders cognitive and mental communication (dementia, a history of psychiatric illness that impedes communication, etc.),
- Having been diagnosed with cancer.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Merzifon Kara Mustafa Paşa Devlet Hastanesi
Amasya, Merzi̇fon, 05300
About this study
Official title: THE IMPACT OF A CANCER SCREENING PROGRAM ON UNCERTAINTY, ANTİCİPATORY ANXIETY, CANCER AWARENESS, AND E-HEALTH LITERACY IN A GROUP OF STROKE PATIENTS
This research aims to evaluate the impact of a cancer awareness education program (Cancer Awareness Programme Via Digital Health Literacy - DigiCAP), designed to enhance digital literacy and applied to stroke patients, on uncertainty, anticipatory anxiety, and cancer awareness. This study was designed as a randomized controlled, single-blind (evaluator-blind), pre-test-post-test experimental design. In the study, all individuals in the sample group were administered the Personal Information Form, the Mishel Illness Uncertainty Scale-Community Form (MIIS-T), the Beck Anxiety Scale (BAS), and the E-Health Literacy Scale as pre-test applications. The training program prepared for the experimental group will be presented. Final tests will be conducted at the end of the training. Individuals will be contacted by phone one month after the training for reminder purposes. Individuals are expected to participate in cancer screening within 3 months.
Read the detailed description
This study was planned in accordance with a single-blind randomized controlled pre-test-post-test experimental research design. The population of the study will consist of individuals diagnosed with stroke who are registered in the Home Care Unit of Amasya Merzifon Kara Mustafa Paşa State Hospital and receiving home care between January 1, 2025 and January 1, 2026. The sample of the study will consist of individuals diagnosed with stroke who are registered in the home care unit, meet the research criteria, and agree to participate in the study. Inclusion Criteria
- Having a stroke diagnosis,
- Being 50 years of age or older,
- Being literate,
- Patients diagnosed with stroke who can communicate will be included in the study. • Having a smartphone or computer,
- Having internet access. • Having a diagnosis of ischemic stroke,
- Caregiver screening awareness? Establishing criteria for caregivers (separate headings) 2.5. Exclusion Criteria
- Impairment of vision, hearing, and speech due to stroke,
- Having any health problem that hinders cognitive and mental communication (dementia, history of psychiatric illness that would impede communication, etc.)
- Having been diagnosed with cancer. Patients diagnosed with stroke in the sample were randomly assigned to intervention and control groups using a simple randomization method. The assignment ratio of patients to the groups was determined as 1:1. The SAS 9.4 software package was used for the randomization of patients to the groups. The blinding of the study was ensured by randomly assigning individuals diagnosed with stroke to the groups. Participants were unaware of which group they were in. In the statistical evaluation phase, the data were divided into two datasets, A and B, and presented to an independent statistician for evaluation. Since the statistician did not know which group was the experimental or control group, statistician blinding was also performed. The research data will be collected using a Personal Information Form, the Mishel Illness Uncertainty Scale, the Beck Anxiety Scale, and the e-Health Literacy Scale. A training booklet will be distributed to participants during the training. The training, planned to strengthen digital literacy, consists of 5 sections. These sections will cover program introduction, digital health literacy, stroke, cancer, and stress management, as outlined below. The total training duration is 55 minutes, with 5-minute breaks. Post-training tests will be administered to participants. Participants will receive reminder calls one month after the training. Participants are expected to attend cancer screenings within 3 months. After the data collection process is complete, a control group will also receive training and a training booklet for ethical reasons.
- Being tested
- CANCER SCREENING PROGRAM
- Keywords
- STROKE, CANCER, CANCER SCREENİNG, E-HEALTH LİTERACY
- Medical subject headings
- Neoplasms, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CANCER SCREENING PROGRAMBehavioural
During home visits, written informed consent will be obtained, the study protocol will be explained, and pre-tests will be administered. Individuals who undergo the pre-test will be randomly assigned to experimental and control groups using a simple random sampling method. The experimental group will receive the planned training, and a training booklet will be provided at the end of the training. One month after the completion of the training, individuals will be visited again at their homes to remind them of their participation in the cancer screening program, and post-tests will be administered. Three months after the start of the study, statements will be obtained from the phone numbers on the patient list to determine whether the experimental group participated in cancer screenings.
| Study group | Role | What they receive |
|---|---|---|
| A CANCER SCREENING PROGRAM | Experimental | The data for the study were collected at Merzifon Kara Mustafa Paşa State Hospital in Merzifon district of Amasya province, and were completed with 44 individuals in the experimental group and 44 individuals in the control group who met the inclusion criteria. In the study, all individuals in the sample group were administered the Personal Information Form, the Mishel Illness Uncertainty Scale-Community Form (MIIS-T), the Beck Anxiety Scale (BAS), and the E-Health Literacy Scale as pre-test applications. The Personal Information Form, Michel Illness Uncertainty Scale-Community Form (MIIS-T), Beck Anxiety Scale (BAS), and E-Health Literacy Scale were administered to individuals diagnosed with stroke in the experimental group. Receives: Behavioral: CANCER SCREENING PROGRAM |
| CONTROL GROUP | No intervention | Following the completion of the data collection process, participants in the control group will receive the same training through home visits and will be given the training booklet. This practice aims to ensure that participants in the control group also benefit from the training, as an ethical requirement. |
What is being measured
The primary outcome is the main question the study is designed to answer.
DATA COLLECTION
Michel Illness Uncertainty Scale-Community Form (IID-T): The scale is evaluated based on three sub-dimensions: "perception of current situation," "perception of understanding," and "uncertainty," and a total score. The scale score is obtained by summing the points given to each item. The possible score ranges from 20 to 100. A higher score indicates increased illness uncertainty.
Measured: about 3 months from the initial stage
DATA COLLECTION
Cancer Fear Scale (CFS): This scale consists of 17 items and 2 sub-dimensions: direct fear and indirect fear. The possible total score ranges from 0 to 68. Higher scores indicate a higher level of cancer fear.
Measured: about 3 months from the initial stage
DATA COLLECTION
e-Health Literacy Scale (e-Health Literacy): This scale consists of eight items measuring internet attitudes, two of which assess internet use. The lowest possible score is 8, and the highest is 40. A high score indicates a high level of e-health literacy.
Measured: about 3 months from the initial stage
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study start1 Jan 2025
- Primary completion1 Jan 2026
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Ondokuz Mayıs UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- Single Group Assingment Randemized Controlled Experimental Design
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 88 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ondokuz Mayıs University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, PELİN UYAR, Ondokuz Mayıs University
- Investigators
- İLKNUR A AVCI, PROF, Study director, ONDOKUZ MAY UNIVERSTY
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07904247
- Sponsor's protocol ID
- 2024-1069
- Acronym
- CANCER
- Status last verified
- Oct 2026
- First submitted
- 11 Jun 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual patient data is not shared in order to protect the individual's privacy and avoid legal repercussions.
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- THE IMPACT OF A CANCER SCREENING PROGRAM ON UNCERTAINTY, ANTİCİPATORY ANXIETY, CANCER AWARENESS, AND E-HEALTH LITERACY IN A GROUP OF STROKE PATIENTS
- ClinicalTrials.gov ID
- NCT07904247
- Acronym / sponsor ID
- CANCER / 2024-1069
- Keywords
- STROKE, CANCER, CANCER SCREENİNG, E-HEALTH LİTERACY
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 88 participants (actual)
- Lead sponsor
- Ondokuz Mayıs UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Jan 2026 (actual)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research aims to evaluate the impact of a cancer awareness education program (Cancer Awareness Programme Via Digital Health Literacy - DigiCAP), designed to enhance digital literacy and applied to stroke patients, on uncertainty, anticipatory anxiety, and cancer awareness. This study was designed as a randomized controlled, single-blind (evaluator-blind), pre-test-post-test experimental design. In the study, all individuals in the sample group were administered the Personal Information Form, the Mishel Illness Uncertainty Scale-Community Form (MIIS-T), the Beck Anxiety Scale (BAS), and the E-Health Literacy Scale as pre-test applications. The training program prepared for the experimental group will be presented. Final tests will be conducted at the end of the training. Individuals will be contacted by phone one month after the training for reminder purposes. Individuals are expected to participate in cancer screening within 3 months.
Detailed description
This study was planned in accordance with a single-blind randomized controlled pre-test-post-test experimental research design. The population of the study will consist of individuals diagnosed with stroke who are registered in the Home Care Unit of Amasya Merzifon Kara Mustafa Paşa State Hospital and receiving home care between January 1, 2025 and January 1, 2026. The sample of the study will consist of individuals diagnosed with stroke who are registered in the home care unit, meet the research criteria, and agree to participate in the study. Inclusion Criteria
- Having a stroke diagnosis,
- Being 50 years of age or older,
- Being literate,
- Patients diagnosed with stroke who can communicate will be included in the study. • Having a smartphone or computer,
- Having internet access. • Having a diagnosis of ischemic stroke,
- Caregiver screening awareness? Establishing criteria for caregivers (separate headings) 2.5. Exclusion Criteria
- Impairment of vision, hearing, and speech due to stroke,
- Having any health problem that hinders cognitive and mental communication (dementia, history of psychiatric illness that would impede communication, etc.)
- Having been diagnosed with cancer. Patients diagnosed with stroke in the sample were randomly assigned to intervention and control groups using a simple randomization method. The assignment ratio of patients to the groups was determined as 1:1. The SAS 9.4 software package was used for the randomization of patients to the groups. The blinding of the study was ensured by randomly assigning individuals diagnosed with stroke to the groups. Participants were unaware of which group they were in. In the statistical evaluation phase, the data were divided into two datasets, A and B, and presented to an independent statistician for evaluation. Since the statistician did not know which group was the experimental or control group, statistician blinding was also performed. The research data will be collected using a Personal Information Form, the Mishel Illness Uncertainty Scale, the Beck Anxiety Scale, and the e-Health Literacy Scale. A training booklet will be distributed to participants during the training. The training, planned to strengthen digital literacy, consists of 5 sections. These sections will cover program introduction, digital health literacy, stroke, cancer, and stress management, as outlined below. The total training duration is 55 minutes, with 5-minute breaks. Post-training tests will be administered to participants. Participants will receive reminder calls one month after the training. Participants are expected to attend cancer screenings within 3 months. After the data collection process is complete, a control group will also receive training and a training booklet for ethical reasons.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Single Group Assingment Randemized Controlled Experimental Design
| Arm | Type | Receives |
|---|---|---|
| A CANCER SCREENING PROGRAM | Experimental | Behavioral: CANCER SCREENING PROGRAMThe data for the study were collected at Merzifon Kara Mustafa Paşa State Hospital in Merzifon district of Amasya province, and were completed with 44 individuals in the experimental group and 44 individuals in the control group who met the inclusion criteria. In the study, all individuals in the sample group were administered the Personal Information Form, the Mishel Illness Uncertainty Scale-Community Form (MIIS-T), the Beck Anxiety Scale (BAS), and the E-Health Literacy Scale as pre-test applications. The Personal Information Form, Michel Illness Uncertainty Scale-Community Form (MIIS-T), Beck Anxiety Scale (BAS), and E-Health Literacy Scale were administered to individuals diagnosed with stroke in the experimental group. |
| CONTROL GROUP | No intervention | –Following the completion of the data collection process, participants in the control group will receive the same training through home visits and will be given the training booklet. This practice aims to ensure that participants in the control group also benefit from the training, as an ethical requirement. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- • Having been diagnosed with a stroke,
Key exclusion criteria (3 listed)
- • Having impaired vision, hearing, and speech due to a stroke,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CANCER SCREENING PROGRAMDuring home visits, written informed consent will be obtained, the study protocol will be explained, and pre-tests will be administered. Individuals who undergo the pre-test will be randomly assigned to experimental and control groups using a simple random sampling method. The experimental group will receive the planned training, and a training booklet will be provided at the end of the training. One month after the completion of the training, individuals will be visited again at their homes to remind them of their participation in the cancer screening program, and post-tests will be administered. Three months after the start of the study, statements will be obtained from the phone numbers on the patient list to determine whether the experimental group participated in cancer screenings. | Behavioural | A CANCER SCREENING PROGRAM |
Primary outcome
DATA COLLECTION
Time frame: about 3 months from the initial stage
Michel Illness Uncertainty Scale-Community Form (IID-T): The scale is evaluated based on three sub-dimensions: "perception of current situation," "perception of understanding," and "uncertainty," and a total score. The scale score is obtained by summing the points given to each item. The possible score ranges from 20 to 100. A higher score indicates increased illness uncertainty.
DATA COLLECTION
Time frame: about 3 months from the initial stage
Cancer Fear Scale (CFS): This scale consists of 17 items and 2 sub-dimensions: direct fear and indirect fear. The possible total score ranges from 0 to 68. Higher scores indicate a higher level of cancer fear.
DATA COLLECTION
Time frame: about 3 months from the initial stage
e-Health Literacy Scale (e-Health Literacy): This scale consists of eight items measuring internet attitudes, two of which assess internet use. The lowest possible score is 8, and the highest is 40. A high score indicates a high level of e-health literacy.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- REPUBLİC OF TURKEY MINISTRY OF HEALTHLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual patient data is not shared in order to protect the individual's privacy and avoid legal repercussions.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
İLKNUR A AVCI, PROF study director
ONDOKUZ MAY UNIVERSTY
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CANCER SCREENING PROGRAM in people with Cancer and Stroke, run by Ondokuz Mayıs University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DATA COLLECTION (time frame: about 3 months from the initial stage). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.